Drug intelligence / Profile preview

Dailyzar

Development stage: Unknown
Lead developer: ADP Pharma Corporation
Modality: Small Molecules
Administration: Oral

Overview

Dailyzar is an oral fixed-dose antihypertensive combination containing **losartan potassium 50 mg** and **amlodipine besilate 5 mg** per film-coated tablet. Losartan blocks angiotensin II type 1 receptors, reducing angiotensin II-mediated vasoconstriction and aldosterone signaling, while amlodipine is a dihydropyridine calcium-channel blocker that reduces calcium influx into vascular smooth muscle. ADP Pharma lists Dailyzar for the management of hypertension; the product is manufactured by Micro Labs. ([adppharma.com](https://www.adppharma.com/prescription-drugs/dailyzar/))

Brand names: Dailyzar

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on Dailyzar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dailyzar.

Explore the full profile